The Korean International Pharmaceutical and Life Engineering Association organized a delegation to visit Wei to seek cooperation

From March 22 to 23, Choi Hyung-jin, President of the Korea International Pharmaceutical and Life Engineering Association, and a group of nine people visited Weihai. Hou Weiqiang, Deputy Director of Weihai Global Partner Business Center, and Zhang Lin, Vice President of Weihai Pharmaceutical and Medical Device Industry Association, received them and accompanied them to visit key enterprises and industrial parks in Weihai's pharmaceutical and medical device industries. They held corporate docking and negotiation activities to promote in-depth cooperation between the two sides in the fields of medicine and medical devices, and to promote deeper investment and trade cooperation between enterprises in more medical fields.

  During their stay in Weihai, the delegation visited key parks and backbone enterprises such as Weihai Medical Device and Biomedicine Industrial Park, Weigao Group, and Dijia Pharmaceutical, and visited the Weihai Pharmaceutical and Medical Device Exhibition Hall to gain an in-depth understanding of the development history of Weihai's pharmaceutical and medical device industry, product technology research and development, and production process flow. They also held in-depth discussions with relevant persons in charge of the park, associations, and enterprises to communicate the business development of both parties, match external cooperation needs, establish a contact and communication mechanism, and negotiate cooperation in related industries and fields.

 After inspecting the Weigao exhibition hall, Chairman Cui Xiangzhen expressed high appreciation for the industrial scale and strategy of Weigao Group. At the Weigao symposium, relevant Weigao officials introduced Weihai's industrial cooperation advantages, investment and business environment, and special platform carriers to the delegation, and welcomed Korean companies to combine their own advantages with Weihai's industrial advantages, market advantages, and resource advantages more closely, to expand a wider Korean market for Weihai companies in the process of deepening cooperation, and to open up new cooperation space in the fields of Chinese and Korean medicine and medical devices.

In the scientific research exhibition hall of Dijia Pharmaceutical Group, there are a variety of drugs for the treatment of hypertension, diabetes and other diseases, such as nifedipine sustained-release tablets and metformin hydrochloride tablets. President Cui Xiangzhen and his delegation discussed the results of the "High-end Biological, Synthetic and Formulation Technology" project. At the symposium, Chang Xiujuan, deputy general manager of Dijia Pharmaceutical Group, gave a detailed introduction to Dijia Group's early cooperation projects and strategic deployment in South Korea. Currently, it has obtained certificates for three products in South Korea. The two sides had in-depth exchanges on the future direction of cooperation and jointly sought broad new prospects for development.

  Finally, the delegation visited the exhibition hall of Weihai Pharmaceutical Equipment Association. Zhang Lin, vice president of the association, briefly introduced the development history of Weihai Pharmaceutical Equipment Association and promoted the association's member units and products. Zhang Lin said that in recent years, the association has kept up with social development trends, actively assumed social responsibilities, and continuously made breakthroughs in promoting the development of Weihai's pharmaceutical industry cluster and strengthening and supplementing the supply chain. As the leading industry in Weihai, the pharmaceutical and medical device industries have a total industrial cluster output value of nearly 100 billion yuan, a large industrial scale, a large number of industry employees, and a strong cluster capacity for cutting-edge medical technology research and development. It is hoped that in the future, we can work together with colleagues from all walks of life to give full play to our respective resource advantages, go hand in hand, and develop together.

  This inspection activity not only broadened the cooperation channels of Weihai's pharmaceutical and medical device industries, but also helped more good projects to join hands with Weihai enterprises by connecting with high-quality association resources, injecting strong impetus into the high-quality development of Weihai's pharmaceutical and medical device industry. In the future, Weihai Pharmaceutical and Medical Device Association will continue to focus on the leading industries, accurately plan foreign cooperation projects, deepen technical service docking, further expand channels for communication and cooperation with Korean companies, build a bridge and bond for the two sides to connect supply and demand, complement each other's advantages, and achieve win-win cooperation, and jointly promote the prosperity and innovative development of the Sino-Korean medical device industry.